Hosing Chitra
Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas M.D. Anderson Cancer Center, Houston, Texas, USA.
Stem Cells Cloning. 2010 May 3;3:69-80. doi: 10.2147/sccaa.s7014.
Although much has been published on the application of autologous and allogeneic hematopoietic stem cell transplantation in patients with follicular lymphoma (FL), no uniform consensus exists among physicians on when to use this strategy. Three large randomized trials failed to show a survival benefit using autologous transplantation for FL patients in first complete remission. Similarly, many Phase II or registry-based studies have also failed to show a survival benefit with autologous transplantation in relapsed or refractory FL patients, although the progression-free survival seems to be prolonged in transplant recipients. Allogeneic stem cell transplantation can cure a subset of patients with FL, but high nonrelapse mortality and morbidity remain a concern. No consensus exists on what conditioning regimen should be used, or how the newer monoclonal antibodies should be incorporated into the transplant paradigm. Here we present a review of the role of autologous and allogeneic hematopoietic stem cell transplantation in patients with FL.
尽管关于自体和异基因造血干细胞移植在滤泡性淋巴瘤（FL）患者中的应用已有大量文献发表，但医生们对于何时采用这一策略尚未达成统一共识。三项大型随机试验未能证明自体移植对处于首次完全缓解期的FL患者有生存获益。同样，许多II期或基于注册登记的研究也未能显示自体移植对复发或难治性FL患者有生存获益，尽管移植受者的无进展生存期似乎有所延长。异基因干细胞移植可治愈一部分FL患者，但高非复发死亡率和发病率仍是一个问题。对于应使用何种预处理方案，或者应如何将新型单克隆抗体纳入移植模式，目前尚无共识。在此，我们对自体和异基因造血干细胞移植在FL患者中的作用进行综述。
